Breakthrough in Nanoparticle Research: Overcoming Challenges in Cancer Treatment

Strategic Insights -

Researchers at Polytechnic University in Timisoara, Romania, have made significant strides in the development of nanocarriers for cancer treatment, according to a study published in Biomedicines. The study describes the creation of polymer-based nanoparticles that can sustain the release of anticancer drugs, such as sorafenib and cisplatin, improving their bioavailability and reducing adverse reactions.

Key Takeaways:

  • The researchers developed a novel method for co-entrapment of sorafenib and cisplatin in nanotherapeutics using a biocompatible and biodegradable copolymer of 12-hydroxystearic acid with e-caprolactone (12CL).
  • The nanoparticles displayed a good production yield and were able to sustain the release of the anticancer drugs, improving their bioavailability and reducing adverse reactions.
  • The incorporation of a bovine serum albumin (BSA) model compound and a iRGD tumour penetrating peptide enhanced the targeting function of the nanoparticles, allowing for better delivery of the drugs to the tumour site.
  • The study demonstrated the potential of polymer-based nanoparticles in improving cancer treatment outcomes by providing a controlled and targeted release of anticancer agents.
  • The researchers, led by Polytechnic University, conducted the study with financial support from the National Research, Development and Innovation Fund of Hungary.
  • Additional authors on the study include Izolda Kantor, Anamaria Todea, Francisc Peter, Zoltan May, Emese Biro, Gyorgy Babos, and Tivadar Feczko.

Statistics:

  • 12-hydroxystearic acid with e-caprolactone (12CL) copolymer was used as the carrier for co-entrapment of sorafenib and cisplatin in nanotherapeutics.
  • The report states that the nanoparticles exhibited a production yield of __% using the double emulsion solvent evaporation method.
  • The study found that the incorporation of BSA model compound and iRGD tumour penetrating peptide resulted in a __% increase in cisplatin incorporation.

Sources:

  • Biomedicines, Mdpi, St Alban-Anlage 66, Ch-4052 Basel, Switzerland.
  • Polytechnic University, Carol Telbisz 6, RO-300001 Timisoara, Romania.